Abstract:An error appeared in the corrected proof publication of this article (Siedner and Sax. "Repurposing Revisited: Exploring the Role of Metformin for Treatment of Coronavirus Disease 2019." Clin Infect Dis ; https://doi.org/10.1093/cid/ciae154). An incorrect citation was used for a study discussed in the manuscript, and the manuscript did not include recent information regarding validity concerns about that trial. In the final paragraph, the sentence "Furthermore, another randomized, placebo-controlled trial of metformin, albeit with a different dosing strategy, showed no benefit [12]" should be updated to:

Correction to “Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection”

Correction to "Scalable Inhibitors of the Nsp3-Nsp4 Coupling in SARS-CoV-2"

Correction: Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Correction to “The SARS-COV-2 Spike Protein Binds Sialic Acids, and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device”

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction to: Mesenchymal stem cells in the treatment of severe COVID-19

Corrigendum: Antimicrobial resistance in the COVID-19 landscape: is there an opportunity for anti-infective antibodies and antimicrobial peptides?

Corrigendum to"Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment" [Bioact Mater 24 (2022) 37-53]

Correction to "Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy"

Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19

Corrigendum: Identification of novel therapeutic candidates against SARS-CoV-2 infections: An application of RNA sequencing toward mRNA based nanotherapeutics

Erratum to: Experimental Search for New Means of Pathogenetic Therapy COVID-19: Inhibitor of H2-Receptors Famotidine Increases the Effect of Oseltamivir on Survival and Immune Status of Mice Infected by A/PR/8/34 (H1N1)

Corrigendum: The cholesterol-binding sequence in monomeric C-reactive protein binds to the SARS-CoV-2 spike receptor-binding domain and blocks interaction with Angiotensin-converting enzyme 2

Correction to "Novel Antiproliferative Chimeric Compounds with Marked Histone Deacetylase Inhibitory Activity"

Erratum: "Interferon-γ liposome: a new system to improve drug delivery in the treatment of lung cancer". Maysa Alhawamdeh, Mohammad Isreb, Abid Aziz, Badie K. Jacob, Diana Anderson and Mojgan Najafzadeh. ERJ Open Res 2021; 7: 00555-2020

Corrigendum to “Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice” [Bioactive materials 6 (2021) 529–542]

Correction: de Jesus et al. Voacanga globosa Spirobisindole Alkaloids Exert Antiviral Activity in HIV Latently Infected Cell Lines by Targeting the NF-κB Cascade: In Vitro and In Silico Investigations. Molecules 2022, 27, 1078

Correction to: Repurposing Revisited: Exploring the Role of Metformin for Treatment of Coronavirus Disease 2019

Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]

Corrigendum: HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy-an in vitro exploration

Corrigendum: Targeting matrix metalloproteases in diabetic wound healing